BXRX - Baudax stock falls as sales team for Anjeso eliminated as pain drug discontinued
- Baudax Bio ( NASDAQ: BXRX ) said in a Dec. 30, 2022 SEC filing that it eliminated its commercial personnel for its first commercial product, pain drug Anjeso (IV meloxicam).
- The company added that on Dec. 28, 2022, the discontinuation of sale of Anjeso was acknowledged by FDA via listing in the Orange Book.
- Baudax noted that it continues to evaluate alternative approaches to the monetization of Anjeso in the U.S. and outside the U.S.
- The company added that BX 1000, an intermediate acting neuromuscular blocking (NMB), is currently enrolling patients in a phase 2 trial in abdominal surgical conditions with a preplanned first interim analysis expected early in 2023, and with a goal to complete enrollment in the full study by the end of Q1 2023.
- BX 2000, an ultrashort acting NMB, is in a dose escalation study in healthy volunteers which Baudax plans to complete in 2023.Meanwhile, BX 3000 is in preclinical studies, according to the company.
- BXRX -8.81% to $2.90 premarket Jan. 3
For further details see:
Baudax stock falls as sales team for Anjeso eliminated as pain drug discontinued